HeartBeam Inc. (NASDAQ: BEAT) announced it has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The patent expands the company's intellectual property portfolio and advances its strategy of developing a multi-modal ambulatory cardiac sensing platform.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.
HeartBeam’s expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor. The company’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. As noted in its press release, cleared indications for use are available at HeartBeam Indications.
For business and technology leaders, this development signals a shift toward more comprehensive remote patient monitoring. The ability to detect heart failure exacerbations and valve abnormalities early could reduce hospital readmissions and healthcare costs, while giving patients greater autonomy in managing their cardiac health. The patent also strengthens HeartBeam’s competitive position in the growing digital health market.
HeartBeam holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. The full press release can be viewed at https://ibn.fm/jgVf0.
